Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Johan Vansteenkiste on Atezolizumab in NSCLC

Johan Vansteenkiste, MD,PhD
Published: Thursday, Oct 01, 2015



Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with non–small cell lung cancer (NSCLC).

In the primary analysis, atezolizumab showed an improved survival advantage over docetaxel compared with results shown in the interim analysis, says Vansteenkiste. This may be due to the fact that immunotherapy tends to have a delayed onset. With longer follow-up, more separation of the survival curves is seen.

Because of this delayed response, results may even further improve, says Vansteenkiste.

<<< View more from the 2015 European Cancer Congress



Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with non–small cell lung cancer (NSCLC).

In the primary analysis, atezolizumab showed an improved survival advantage over docetaxel compared with results shown in the interim analysis, says Vansteenkiste. This may be due to the fact that immunotherapy tends to have a delayed onset. With longer follow-up, more separation of the survival curves is seen.

Because of this delayed response, results may even further improve, says Vansteenkiste.

<<< View more from the 2015 European Cancer Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x